Biocon and Duopharma Biotech secured over MYR225 million in Malaysian insulin contracts, reinforcing affordable diabetes treatment, strengthening local manufacturing, and…
Duopharma Biotech reports 15.4% revenue growth in Q3 FY2024, driven by strong public health sales and new government supply contracts.
This website uses cookies.